Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2

A R Gottschalk, L H Boise, C B Thompson, J Quintáns, A R Gottschalk, L H Boise, C B Thompson, J Quintáns

Abstract

Cyclosporin A, FK-506, and rapamycin are immunosuppressants often used as pharmacological probes to study lymphocyte activation and physiological cell death (PCD). Because cyclosporin A and FK-506 are known to prevent PCD in T-cell hybridomas and thymocytes, we used these reagents, as well as rapamycin, to determine whether they alter the pathway leading to apoptosis in murine WEHI-231 cells following surface IgM cross-linking. We observed that the immunosuppressants themselves induced PCD in WEHI-231 cells, but only in sublines susceptible to anti-IgM-mediated apoptosis. PCD was preceded by growth arrest and characterized by the DNA fragmentation pattern typical of apoptosis. In B-cell lines resistant to anti-immunoglobulin- and immunosuppressant-induced PCD, cyclosporin A, FK-506, and rapamycin caused growth arrest. PCD was also induced by inhibitors of protein synthesis in WEHI-231 cells but not in the mature B-cell line BAL-17. Immunosuppressant-induced and protein synthesis inhibitor-induced PCD, but not growth arrest, could be prevented by the overexpression of bcl-xL, while transfection with bcl-2 did not affect PCD or cell cycle arrest. These results suggest that bcl-2 and bcl-xL may control partially independent systems to inhibit PCD in lymphoid cells and that PCD in B and T cells may be differentially regulated.

References

    1. J Exp Med. 1986 Jul 1;164(1):156-64
    1. Science. 1984 Nov 2;226(4674):544-7
    1. Nature. 1989 Jun 22;339(6226):625-6
    1. Nature. 1989 Oct 26;341(6244):758-60
    1. J Immunol. 1990 Jan 1;144(1):251-8
    1. Mol Cell Biol. 1990 May;10(5):1901-7
    1. J Immunol. 1990 May 1;144(9):3602-10
    1. Mol Cell Biol. 1990 Jun;10(6):3003-12
    1. Eur J Immunol. 1990 Jun;20(6):1405-7
    1. Eur J Immunol. 1990 Aug;20(8):1685-90
    1. Eur J Immunol. 1990 Oct;20(10):2277-83
    1. Nature. 1990 Nov 22;348(6299):334-6
    1. Proc Natl Acad Sci U S A. 1990 Dec;87(23):9231-5
    1. Cell. 1991 Aug 23;66(4):807-15
    1. Cell. 1991 Nov 29;67(5):879-88
    1. Cell. 1991 Nov 29;67(5):889-99
    1. Int J Immunopharmacol. 1991;13(6):677-85
    1. Proc Natl Acad Sci U S A. 1992 May 1;89(9):3686-90
    1. Annu Rev Immunol. 1992;10:519-60
    1. Nature. 1992 Jul 2;358(6381):70-3
    1. Cell. 1992 Jun 26;69(7):1227-36
    1. Science. 1992 Aug 14;257(5072):973-7
    1. Eur J Immunol. 1992 Oct;22(10):2513-7
    1. Transplantation. 1992 Sep;54(3):543-7
    1. J Biol Chem. 1993 Feb 15;268(5):3734-8
    1. EMBO J. 1993 Apr;12(4):1555-60
    1. Eur J Immunol. 1993 Aug;23(8):2011-5
    1. Cell. 1993 Aug 27;74(4):597-608
    1. Cell. 1993 Aug 27;74(4):609-19
    1. J Immunol. 1993 Sep 15;151(6):2965-73
    1. J Biol Chem. 1993 Oct 25;268(30):22737-45
    1. Int Immunol. 1994 Jan;6(1):121-30
    1. Br J Cancer. 1972 Aug;26(4):239-57
    1. Int Rev Cytol. 1980;68:251-306
    1. Cell. 1989 Apr 7;57(1):79-88

Source: PubMed

3
S'abonner